ReviewJournal of clinical and experimental hepatology2013
Chronic hepatitis e virus infection and treatment.
Review in Journal of clinical and experimental hepatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 74 citations in OpenAlex.
- Detection of Infectious Hepatitis E Virus in Retail Pork Pâté After Optimization of Extraction Protocols.Viruses · 2026Article
- Role of microRNAs in chronic hepatitis E viral infection.Bioinformation · 2025Article
- Identification of key candidates associated with chronic hepatitis E viral infection.Bioinformation · 2025Article
- Viral Hepatitis: Host Immune Interaction, Pathogenesis and New Therapeutic Strategies.Pathogens (Basel, Switzerland) · 2024Review
- Combining RNA Interference and RIG-I Activation to Inhibit Hepatitis E Virus Replication.Viruses · 2024Article
- Antagonism of epidermal growth factor receptor signaling favors hepatitis E virus life cycle.Journal of virology · 2024Article
- Hepatitis E virus infections.World journal of virology · 2024Article
- Common and Potential Emerging Foodborne Viruses: A Comprehensive Review.Life (Basel, Switzerland) · 2024Review
- Discovery of Hepatitis E and Its Impact on Global Health: A Journey of 44 Years about an Incredible Human-Interest Story.Viruses · 2023Review
- Quantification of host proteomic responses to genotype 4 hepatitis E virus replication facilitated by pregnancy serum.Virology journal · 2023Article
- Development of Recombinant Infectious Hepatitis E Virus Harboring the nanoKAZ Gene and Its Application in Drug Screening.Journal of virology · 2022Article
- HEV infection in stem cell transplant recipients-retrospective study of EBMT Infectious Diseases Working Party.Bone marrow transplantation · 2022Observational
- Quantitative Methods for the Prioritization of Foods Implicated in the Transmission of Hepatititis E to Humans in Italy.Foods (Basel, Switzerland) · 2021Article
- Prevalence and clinical correlation of hepatitis E virus antibody in the patients' serum samples from a tertiary care hospital in Thailand during 2015-2018.Virology journal · 2021Article
- Emerging Hepatotropic Viruses in Cats: A Brief Review.Viruses · 2021Review
- Identification of the interferon-inducible GTPase GBP1 as major restriction factor for the Hepatitis E virus.Journal of virology · 2021Article
- Optimization and Implementation of the Virus Extraction Method for Hepatitis E Virus Detection from Raw Pork Liver.Food and environmental virology · 2021Article
- Implications of Hepatitis E Virus in Blood Transfusions, Hemodialysis, and Solid Organ Transplants.Medicina (Kaunas, Lithuania) · 2020Review
- A Systematic Review of the Extra-Hepatic Manifestations of Hepatitis E Virus Infection.Medical sciences (Basel, Switzerland) · 2020Review
- Viral Hepatitis E and Chronicity: A Growing Public Health Concern.Frontiers in microbiology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is now well accepted that hepatitis E virus (HEV) infection can induce chronic hepatitis and cirrhosis in immunosuppressed patients. Chronic genotype-3 HEV infections were first reported in patients with a solid-organ transplant. Thereafter, cases of chronic HEV infection have been reported in patients with hematological disease and in those who are human immunodeficiency virus (HIV)-positive. HEV-associated extra-hepatic manifestations, including neurological symptoms, kidney injuries, and hematological disorders, have been also reported. In transplant patients, reducing the dosage of immunosuppressive drugs allows the virus to be cleared in some patients. In the remaining patients, as well as hematological patients and patients who are HIV-positive, anti-viral therapies, such as pegylated interferon and ribavirin, have been found to be efficient in eradicating HEV infection. This review summarizes our current knowledge of chronic HEV infection, its treatment, and the extra-hepatic manifestations induced by HEV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.